The comprehensive genetic characterization of muscle-invasive BLCA has shown that ~34% of tissues harbor mutations in DDR genes such as ATR, MDC1, CHK1/2, ATM, BRCA1/2, and RAD52, suggesting that PARP inhibition can be effective in advanced BLCA [44, 45]. The gene discussed is ATM; the disease is bladder transitional cell carcinoma.